CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
You may also be interested in...
Demonstration would ‘build on’ Medicare price controls established by the Inflation Reduction Act, White House says.
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.
CMS principal deputy administrator Jonathan Blum discusses how the agency is thinking about implementing the drug pricing reforms now under consideration in the US Congress.